MARKET

HNSBF

HNSBF

Hansa Medical AB
EXMKT
3.300
NaN%
Closed 09:30 01/02 EST
OPEN
--
PREV CLOSE
3.300
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
3.300
52 WEEK LOW
3.300
MARKET CAP
279.72M
P/E (TTM)
-3.4832
1D
5D
1M
3M
1Y
5Y
1D
Hansa Biopharma Files FDA BLA for Imlifidase in High-Risk Kidney Transplant Patients
TipRanks · 12/19/2025 20:02
Hansa Biopharma to Present at J.P. Morgan Healthcare Conference to Boost Investor Visibility
TipRanks · 12/19/2025 11:04
Hansa Biopharma price target lowered to SEK 111 from SEK 132 at H.C. Wainwright
TipRanks · 12/17/2025 11:11
Hansa Biopharma’s Phase 3 Trial for Anti-GBM Disease Shows Mixed Results
TipRanks · 12/16/2025 22:44
Hansa Biopharma Strengthens European and International Operations
TipRanks · 12/15/2025 06:33
Hansa Biopharma GAAP EPS of -SEK1.75, revenue of SEK 30.8M
Seeking Alpha · 10/30/2025 12:45
Weekly Report: what happened at HNSBF last week (0908-0912)?
Weekly Report · 09/15/2025 11:36
Weekly Report: what happened at HNSBF last week (0901-0905)?
Weekly Report · 09/08/2025 11:38
More
About HNSBF
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Webull offers Hansa Biopharma AB stock information, including EXMKT: HNSBF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HNSBF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HNSBF stock methods without spending real money on the virtual paper trading platform.